Phase 1b/2 trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treatment of patients with MGMT silenced, microsatellite stable metastatic colorectal cancer.

2024-515580-64-00 Phase I and Phase II (Integrated) - First administration to humans Ongoing, recruiting

Start 31 Dec 2020 · Status Ongoing, recruiting · 1 EU/EEA countries · 6 sites

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - First administration to humans
Status Ongoing, recruiting
Participants planned 33
Countries 1
Sites 6

metastatic colorectal cancer

Key facts

Sponsor
Fondazione IRCCS Istituto Nazionale Dei Tumori
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04], Diseases [C] - Digestive System Diseases [C06]
Trial duration
31 Dec 2020 → ongoing
Decision date (initial)
2024-08-12
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-515580-64-00
EudraCT number
2020-002315-22
WHO UTN
U0000-0000-0000
ClinicalTrials.gov
NCT00000000
ISRCTN
ISRCTN00000000

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

metastatic colorectal cancer

VersionLevelCodeTermSystem organ class
27.0 LLT 10052362 Metastatic colorectal cancer 10029104
20.0 SOC 10029104 Neoplasms benign malignant and unspecified (incl cysts and polyps) 2

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Fondazione IRCCS Istituto Nazionale Dei Tumori

Sponsor organisation
Fondazione IRCCS Istituto Nazionale Dei Tumori
Address
Via Giacomo Venezian 1
City
Milan
Postcode
20133
Country
Italy

Scientific contact point

Organisation
Fondazione IRCCS Istituto Nazionale Dei Tumori
Contact name
S.C. Oncologia medica

Public contact point

Organisation
Fondazione IRCCS Istituto Nazionale Dei Tumori
Contact name
public relations office

Locations

1 EU/EEA country · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ongoing, recruiting 33 6
Rest of world 0

Investigational sites

Italy

6 sites · Ongoing, recruiting
Azienda Ospedaliero Universitaria Pisana
Oncologia, Via Paradisa 2, 56124, Pisa
Azienda Unita Sanitaria Locale Della Romagna
Oncologia, Viale Stradone 9, 48018, Faenza
Fondazione IRCCS Istituto Nazionale Dei Tumori
Oncologia Medica 1, Via Giacomo Venezian 1, 20133, Milan
Istituto Oncologico Veneto
Oncologia medica, Via Gattamelata 64, 35128, Padova
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
department of medical and surgical sciences, Largo Francesco Vito 1, 00168, Rome
Azienda Sanitaria Universitaria Friuli Centrale
Oncologia, Piazzale Santa Maria Della Misericordia 15, 33100, Udine

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2020-12-31 2020-12-31

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-05 Italy Acceptable
2024-07-17
2024-08-12
2 SUBSTANTIAL MODIFICATION SM-1 2024-12-19 Italy Acceptable
2025-03-17
2025-04-10
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-05-23 Italy Acceptable
2025-03-17
2025-05-23
4 NON SUBSTANTIAL MODIFICATION NSM-2 2025-12-22 Italy Acceptable
2025-03-17
2025-12-22